Novartis to Provide Cholesterol-Fighting Drug Leqvio in UK

 Novartis AG has reached a deal to provide its cholesterol-lowering medicine Leqvio to patients via the U.K.'s National Health Service, the Swiss pharmaceutical company said Wednesday.

Over the course of three years, around 300,000 patients should be treated with Leqvio (inclisiran), Novartis said. The patients targeted are those at high risk of having a second cardiovascular event.

The treatment is part of a population health-management approach and aims to reduce patients' long-term elevated LDL cholesterol, a key modifiable risk factor in cardiovascular disease, the company said.

The collaboration with the NHS follows final recommendation for Leqvio from the U.K.'s medicines regulator, NICE.

https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-to-Provide-Cholesterol-Fighting-Drug-Leqvio-in-UK-36294364/